Current Report Filing (8-k)
July 27 2020 - 3:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
July
22, 2020
|
Date
of Report (Date of earliest event reported)
|
Immune
Therapeutics, Inc.
|
(Exact
name of registrant as specified in its charter)
|
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.
|
2431
Aloma Ave, Suite 124, Winter Park, FL
|
|
32792
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code 888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol
|
|
Name
of exchange on which registered
|
Common
stock $0.0001 per share
|
|
IMUN
|
|
OTC
Markets
|
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On
July 22, 2020, director Kevin J. Phelps, interim president and CEO of Immune Therapeutics, Inc. (“Immune” or the “Company”)
entered into a three-year executive employment agreement (the “Agreement”) with the Company to serve as president
and CEO. This agreement was formally approved by the Company’s Board as of July 24, 2020 with Mr. Phelps abstaining. While
fully effective, the parties may expand and restate the Agreement within thirty days.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
|
|
Date:
July 27, 2020
|
By:
|
/s/
Roscoe M. Moore
|
|
|
|
Dr.
Roscoe M. Moore Jr., Chairman
|
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024